Increasing role of the cancer chemotherapeutic doxorubicin in cellular metabolism

Author:

Meredith Ann-Marie1,Dass Crispin R12

Affiliation:

1. School of Pharmacy, Curtin University, Bentley, WA, Australia

2. Curtin Biosciences Research Precinct, Bentley, WA, Australia

Abstract

Abstract Objectives The use of doxorubicin, a drug utilised for many years to treat a wide variety of cancers, has long been limited due to the significant toxicity that can occur not only during, but also years after treatment. It has multiple mechanisms of action including the intercalation of DNA, inhibition of topoisomerase II and the production of free radicals. We review the literature, with the aim of highlighting the role of drug concentration being an important determinant on the unfolding cell biological events that lead to cell stasis or death. Methods The PubMed database was consulted to compile this review. Key findings It has been found that the various mechanisms of action at the disposal of doxorubicin culminate in either cell death or cell growth arrest through various cell biological events, such as apoptosis, autophagy, senescence and necrosis. Which of these events is the eventual cause of cell death or growth arrest appears to vary depending on factors such as the patient, cell and cancer type, doxorubicin concentration and the duration of treatment. Conclusions Further understanding of doxorubicin's influence on cell biological events could lead to an improvement in the drug's efficacy and reduce toxicity.

Publisher

Oxford University Press (OUP)

Subject

Pharmaceutical Science,Pharmacology

Reference81 articles.

1. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity;Minotti;Pharmacol Rev,2004

2. Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity;Keizer;Pharmacol Ther,1990

3. Myocardial performance index and biochemical markers for early detection of doxorubicin-induced cardiotoxicity in children with acute lymphoblastic leukaemia;Ruggiero;Int J Clin Oncol,2013

4. Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy;Batist;Exp Opin Pharmacother,2002

5. Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study;Marina;Clin Cancer Res,2002

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3